A Phase II Study in Healthy Adult and Elderly Populations to Assess the Safety and Immunogenicity of a Sanofi Pasteur H1N1 Influenza Vaccine Administered at Different Dose Levels Given With and Without GlaxoSmithKline AS03 Adjuvant.
Phase of Trial: Phase II
Latest Information Update: 21 Apr 2013
At a glance
- Drugs Influenza A virus vaccine-H1N1 (Primary) ; AS03A
- Indications Influenza A virus H1N1 subtype
- Focus Adverse reactions; Pharmacodynamics
- 10 Jul 2012 Results published in the Journal of Infectious Diseases.
- 04 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Dec 2009 Actual patient number (789) added as reported by ClinicalTrials.gov.